Microcap Rising on Expansion Into Rapid Diagnostics

Sponsored:

Wednesday, December 31, 2025

Healthcare is steadily shifting out of clinics and into consumers’ homes, driven by demand for speed, privacy, and convenience. Few areas illustrate that trend more clearly than diagnostic testing, where at-home solutions are gaining traction as barriers like stigma, wait times, and access continue to limit traditional care models.

Shares of Hydreight Technologies Inc. (TSX-V: NURS) (OTCQB: HYDTF) are moving higher Wednesday after the company announced its entry into the at-home STI pre-screening market through an exclusive distribution agreement with Health Screen Collective. The news also carries implications for Victory Square Technologies (CSE: VST) (OTC: VSQTF), a strategic partner in Hydreight’s direct-to-consumer platform initiatives.

Under the agreement, Hydreight becomes the exclusive distributor of Health Screen Collective’s at-home STI pre-screen testing kits across its national platform. The company disclosed it has already secured approximately 50,000 pre-orders, with initial deliveries expected to begin in early 2026. The agreement positions Hydreight squarely within one of the most under-addressed segments of preventive healthcare.

Sexually transmitted infections remain widespread and often undiagnosed. Data from the Centers for Disease Control and Prevention indicates roughly one in five people in the United States is living with an STI at any given time, while the World Health Organization estimates more than one million curable STIs are acquired globally every day. Despite the scale of the issue, testing rates remain constrained by privacy concerns and access challenges.

Health Screen Collective’s kits are designed to deliver pre-screening results in minutes rather than days using validated lateral-flow immunoassay technology. The tests allow individuals to collect samples privately at home and screen for multiple common infections, including chlamydia, gonorrhea, trichomonas, and several others, depending on the selected panel. Product validation data indicates high sensitivity and specificity, supporting their role as reliable first-step screening tools.

What differentiates this launch is Hydreight’s ability to integrate testing into a broader digital care pathway. Through its platform, users can move from pre-screening to licensed medical review, confirmatory testing, clinical consultation, and treatment coordination where appropriate. This creates an end-to-end workflow rather than a standalone product, addressing both early detection and follow-through.

Management highlighted that STI screening is a high-frequency category driven by ongoing public health guidelines and repeat testing needs. The initial 50,000 pre-orders suggest early demand from enterprise and distribution partners seeking scalable, compliant at-home solutions embedded within digital healthcare infrastructure.

Victory Square Technologies plays a supporting role through its partnership with Hydreight on the VSDHOne direct-to-consumer platform. That platform enables businesses to rapidly launch compliant online healthcare brands across all 50 states, covering categories such as sexual health, hormone therapy, and personalized treatments. The STI testing initiative fits squarely within that broader strategy.

Shares of NURS are up 9.3 percent at C$4.70 in Wednesday afternoon trading, while HYDTF is higher by 8.5 percent. Victory Square shares are also participating in the move; with VST gaining 7.0% to C$0.76, while VSQTF has risen 8.9% to $0.557.

Sponsored: